Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Published: 30 June 2020
Expert Insight
Glen Firestone

The first two CAR-T therapies demonstrated impressive efficacy data, and following their FDA approval in 2017, there has been tremendous excitement in the scientific and investment community for immuno-oncology cell therapies. In the last few years, there has been unprecedented growth in the number of biotech startups and cell therapy clinical trials, supported by an infusion of cash from private (venture capital) and public (capital markets) entities, as well as acquisitions and strategic partnerships with pharmaceutical companies. It is anticipated that the introduction of these novel cell therapies will dramatically improve patients’ lives and fundamentally transform the healthcare landscape in this new decade. This commercially oriented article focuses on innovative immuno-oncology cell therapies and explores key opportunities and challenges facing biotech companies, commercial plans to drive success, and strategies to disrupt the market.

Read now